Drug Profile
MDGN 201
Alternative Names: Epodure™; Erythropoietin gene therapy - Avalo Therapeutics; MDGN 201 TARGTepo secreting EPO; MDGN-201; TARGTEPOLatest Information Update: 30 Aug 2021
Price :
$50
*
At a glance
- Originator Medgenics
- Developer Aevi Genomic Medicine
- Class Antianaemics; Erythropoietins; Gene therapies
- Mechanism of Action Erythropoiesis stimulants; Gene transference; Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Anaemia; Beta-thalassaemia; Myelodysplastic syndromes
Most Recent Events
- 26 Aug 2021 Cerecor is now called Avalo Therapeutics
- 03 Feb 2020 Aevi Genomic Medicine has been acquired and merged into Cerecor
- 31 Aug 2018 Discontinued - Phase-II for Anaemia (In the elderly, In adults) in USA (SC)